US Stock MarketDetailed Quotes

BIIB Biogen

Watchlist
  • 145.805
  • -0.985-0.67%
Trading Dec 19 11:03 ET
21.25BMarket Cap13.18P/E (TTM)

Biogen Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-2.55%2.47B
0.36%2.46B
-7.00%2.29B
-3.32%9.84B
-6.20%2.39B
0.87%2.53B
-5.14%2.46B
-2.72%2.46B
-7.36%10.17B
-6.94%2.54B
Operating revenue
-0.47%2.22B
0.36%2.46B
-8.09%1.9B
-7.76%8.94B
-3.58%2.27B
-6.43%2.23B
-1.41%2.46B
-3.23%2.06B
-7.78%9.69B
-9.79%2.35B
Cost of revenue
-3.17%638.7M
-7.88%546M
-18.20%542.2M
11.20%2.53B
8.30%618.3M
40.49%659.6M
22.46%592.7M
-12.08%662.8M
7.99%2.28B
-13.51%570.9M
Gross profit
-2.33%1.83B
2.98%1.92B
-2.88%1.75B
-7.51%7.3B
-10.39%1.77B
-8.25%1.87B
-11.49%1.86B
1.25%1.8B
-11.01%7.9B
-4.85%1.97B
Operating expense
-18.66%1.33B
-2.01%1.22B
-8.15%1.18B
9.57%5.47B
-9.30%1.31B
34.72%1.64B
3.66%1.24B
12.91%1.28B
-17.66%4.99B
-2.93%1.44B
Selling and administrative expenses
-25.35%588.4M
1.06%553.8M
-3.88%581.5M
6.08%2.55B
-3.84%608.5M
39.93%788.2M
-4.30%548M
-4.71%605M
-10.12%2.4B
-19.69%632.8M
Research and development costs
-26.29%542.7M
-12.03%513.9M
-20.63%452.9M
10.35%2.46B
-5.10%570.9M
34.07%736.3M
10.52%584.2M
3.43%570.6M
-10.80%2.23B
-14.00%601.6M
Depreciation amortization depletion
113.96%130.3M
64.27%86.9M
55.98%78.3M
-34.24%240.6M
-56.23%76.6M
7.79%60.9M
-21.63%52.9M
-24.96%50.2M
-58.48%365.9M
156.98%175M
-Depreciation and amortization
113.96%130.3M
64.27%86.9M
55.98%78.3M
-34.24%240.6M
-56.23%76.6M
7.79%60.9M
-21.63%52.9M
-24.96%50.2M
-58.48%365.9M
156.98%175M
Other operating expenses
37.23%69.3M
9.67%62.4M
14.89%65.6M
3,056.76%218.8M
54.26%54.3M
11.48%50.5M
93.54%56.9M
148.68%57.1M
-202.78%-7.4M
152.30%35.2M
Operating profit
111.41%496.4M
12.97%701.9M
10.19%570M
-36.90%1.83B
-13.40%457.7M
-71.53%234.8M
-31.50%621.3M
-19.39%517.3M
3.34%2.9B
-9.74%528.5M
Net non-operating interest income expense
-250.16%-48.2M
-253.73%-41.2M
-381.52%-51.8M
118.82%29.6M
-873.47%-47.7M
189.17%32.1M
150.38%26.8M
129.11%18.4M
35.16%-157.3M
92.28%-4.9M
Non-operating interest income
-87.90%11.6M
-73.52%20.1M
-78.49%17.4M
209.63%276.5M
-52.30%23.8M
301.26%95.9M
502.38%75.9M
2,689.66%80.9M
711.82%89.3M
1,682.14%49.9M
Non-operating interest expense
-6.27%59.8M
24.85%61.3M
10.72%69.2M
0.12%246.9M
30.47%71.5M
6.51%63.8M
-25.38%49.1M
-5.45%62.5M
-2.76%246.6M
-17.35%54.8M
Other net income (expense)
100.69%2.8M
-36.67%38M
45.17%-53.4M
-166.56%-563.9M
-247.63%-118.4M
-170.07%-408.1M
-85.57%60M
57.85%-97.4M
203.29%847.2M
168.55%80.2M
Gain on sale of security
110.40%34.2M
-143.43%-42M
54.75%-40M
-9.21%-341.6M
80.06%-21.2M
-464.01%-328.7M
199.28%96.7M
55.67%-88.4M
63.08%-312.8M
9.15%-106.3M
Special income (charges)
59.74%-30.6M
338.37%82M
-19.79%-11.5M
-118.70%-218.8M
-157.64%-98.8M
-115.50%-76M
-106.38%-34.4M
69.03%-9.6M
3,478.29%1.17B
10,612.50%171.4M
-Less：Restructuring and merger&acquisition
-59.74%30.6M
-80.81%6.6M
19.79%11.5M
380.51%218.8M
152.44%98.8M
471.43%76M
-47.96%34.4M
-69.03%9.6M
-53.85%-78M
-11,675.00%-188.4M
-Less:Other special charges
----
----
----
----
----
----
----
----
4,994.44%917M
--17M
-Gain on sale of business
----
----
----
--0
----
----
----
----
--1.51B
--0
-Gain on sale of property,plant,equipment
--0
--88.6M
----
--0
--0
--0
--0
----
--503.7M
--0
Other non- operating income (expenses)
76.47%-800K
13.04%-2M
-416.67%-1.9M
65.35%-3.5M
-89.40%1.6M
-300.00%-3.4M
91.22%-2.3M
185.71%600K
-80.36%-10.1M
1,043.75%15.1M
Income before tax
419.41%451M
-1.33%698.7M
6.05%464.8M
-63.90%1.3B
-51.71%291.6M
-110.30%-141.2M
-44.22%708.1M
26.17%438.3M
105.81%3.59B
49.09%603.8M
Income tax
185.73%62.5M
0.26%115.1M
40.83%71.4M
-78.62%135.3M
-21.36%42.7M
-130.86%-72.9M
-47.02%114.8M
-59.63%50.7M
1,105.33%632.8M
-87.75%54.3M
Earnings from equity interest net of tax
----
----
----
--0
----
----
----
----
-92.55%2.6M
--0
Net income
668.81%388.5M
-1.63%583.6M
1.50%393.4M
-60.78%1.16B
-54.70%248.9M
-106.02%-68.3M
-43.96%593.3M
77.39%387.6M
71.43%2.96B
2,780.49%549.5M
Net income continuous Operations
668.81%388.5M
-1.63%583.6M
1.50%393.4M
-60.78%1.16B
-54.70%248.9M
-106.02%-68.3M
-43.96%593.3M
77.39%387.6M
71.43%2.96B
2,780.49%549.5M
Minority interest income
0
0
0
100.47%400K
11.11%-800K
-200.00%-200K
142.86%1.7M
99.65%-300K
-149.74%-85.3M
99.77%-900K
Net income attributable to the parent company
670.48%388.5M
-1.35%583.6M
1.42%393.4M
-61.89%1.16B
-54.63%249.7M
-106.00%-68.1M
-44.08%591.6M
27.68%387.9M
95.80%3.05B
49.48%550.4M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
670.48%388.5M
-1.35%583.6M
1.42%393.4M
-61.89%1.16B
-54.63%249.7M
-106.00%-68.1M
-44.08%591.6M
27.68%387.9M
95.80%3.05B
49.48%550.4M
Basic earnings per share
668.09%2.67
-1.96%4.01
0.74%2.71
-61.74%8.02
-54.97%1.72
-105.98%-0.47
-43.59%4.09
30.58%2.69
100.77%20.96
52.19%3.82
Diluted earnings per share
665.96%2.66
-1.72%4
1.12%2.7
-61.81%7.97
-54.88%1.71
-105.99%-0.47
-43.78%4.07
29.61%2.67
100.67%20.87
51.60%3.79
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue -2.55%2.47B0.36%2.46B-7.00%2.29B-3.32%9.84B-6.20%2.39B0.87%2.53B-5.14%2.46B-2.72%2.46B-7.36%10.17B-6.94%2.54B
Operating revenue -0.47%2.22B0.36%2.46B-8.09%1.9B-7.76%8.94B-3.58%2.27B-6.43%2.23B-1.41%2.46B-3.23%2.06B-7.78%9.69B-9.79%2.35B
Cost of revenue -3.17%638.7M-7.88%546M-18.20%542.2M11.20%2.53B8.30%618.3M40.49%659.6M22.46%592.7M-12.08%662.8M7.99%2.28B-13.51%570.9M
Gross profit -2.33%1.83B2.98%1.92B-2.88%1.75B-7.51%7.3B-10.39%1.77B-8.25%1.87B-11.49%1.86B1.25%1.8B-11.01%7.9B-4.85%1.97B
Operating expense -18.66%1.33B-2.01%1.22B-8.15%1.18B9.57%5.47B-9.30%1.31B34.72%1.64B3.66%1.24B12.91%1.28B-17.66%4.99B-2.93%1.44B
Selling and administrative expenses -25.35%588.4M1.06%553.8M-3.88%581.5M6.08%2.55B-3.84%608.5M39.93%788.2M-4.30%548M-4.71%605M-10.12%2.4B-19.69%632.8M
Research and development costs -26.29%542.7M-12.03%513.9M-20.63%452.9M10.35%2.46B-5.10%570.9M34.07%736.3M10.52%584.2M3.43%570.6M-10.80%2.23B-14.00%601.6M
Depreciation amortization depletion 113.96%130.3M64.27%86.9M55.98%78.3M-34.24%240.6M-56.23%76.6M7.79%60.9M-21.63%52.9M-24.96%50.2M-58.48%365.9M156.98%175M
-Depreciation and amortization 113.96%130.3M64.27%86.9M55.98%78.3M-34.24%240.6M-56.23%76.6M7.79%60.9M-21.63%52.9M-24.96%50.2M-58.48%365.9M156.98%175M
Other operating expenses 37.23%69.3M9.67%62.4M14.89%65.6M3,056.76%218.8M54.26%54.3M11.48%50.5M93.54%56.9M148.68%57.1M-202.78%-7.4M152.30%35.2M
Operating profit 111.41%496.4M12.97%701.9M10.19%570M-36.90%1.83B-13.40%457.7M-71.53%234.8M-31.50%621.3M-19.39%517.3M3.34%2.9B-9.74%528.5M
Net non-operating interest income expense -250.16%-48.2M-253.73%-41.2M-381.52%-51.8M118.82%29.6M-873.47%-47.7M189.17%32.1M150.38%26.8M129.11%18.4M35.16%-157.3M92.28%-4.9M
Non-operating interest income -87.90%11.6M-73.52%20.1M-78.49%17.4M209.63%276.5M-52.30%23.8M301.26%95.9M502.38%75.9M2,689.66%80.9M711.82%89.3M1,682.14%49.9M
Non-operating interest expense -6.27%59.8M24.85%61.3M10.72%69.2M0.12%246.9M30.47%71.5M6.51%63.8M-25.38%49.1M-5.45%62.5M-2.76%246.6M-17.35%54.8M
Other net income (expense) 100.69%2.8M-36.67%38M45.17%-53.4M-166.56%-563.9M-247.63%-118.4M-170.07%-408.1M-85.57%60M57.85%-97.4M203.29%847.2M168.55%80.2M
Gain on sale of security 110.40%34.2M-143.43%-42M54.75%-40M-9.21%-341.6M80.06%-21.2M-464.01%-328.7M199.28%96.7M55.67%-88.4M63.08%-312.8M9.15%-106.3M
Special income (charges) 59.74%-30.6M338.37%82M-19.79%-11.5M-118.70%-218.8M-157.64%-98.8M-115.50%-76M-106.38%-34.4M69.03%-9.6M3,478.29%1.17B10,612.50%171.4M
-Less：Restructuring and merger&acquisition -59.74%30.6M-80.81%6.6M19.79%11.5M380.51%218.8M152.44%98.8M471.43%76M-47.96%34.4M-69.03%9.6M-53.85%-78M-11,675.00%-188.4M
-Less:Other special charges --------------------------------4,994.44%917M--17M
-Gain on sale of business --------------0------------------1.51B--0
-Gain on sale of property,plant,equipment --0--88.6M------0--0--0--0------503.7M--0
Other non- operating income (expenses) 76.47%-800K13.04%-2M-416.67%-1.9M65.35%-3.5M-89.40%1.6M-300.00%-3.4M91.22%-2.3M185.71%600K-80.36%-10.1M1,043.75%15.1M
Income before tax 419.41%451M-1.33%698.7M6.05%464.8M-63.90%1.3B-51.71%291.6M-110.30%-141.2M-44.22%708.1M26.17%438.3M105.81%3.59B49.09%603.8M
Income tax 185.73%62.5M0.26%115.1M40.83%71.4M-78.62%135.3M-21.36%42.7M-130.86%-72.9M-47.02%114.8M-59.63%50.7M1,105.33%632.8M-87.75%54.3M
Earnings from equity interest net of tax --------------0-----------------92.55%2.6M--0
Net income 668.81%388.5M-1.63%583.6M1.50%393.4M-60.78%1.16B-54.70%248.9M-106.02%-68.3M-43.96%593.3M77.39%387.6M71.43%2.96B2,780.49%549.5M
Net income continuous Operations 668.81%388.5M-1.63%583.6M1.50%393.4M-60.78%1.16B-54.70%248.9M-106.02%-68.3M-43.96%593.3M77.39%387.6M71.43%2.96B2,780.49%549.5M
Minority interest income 000100.47%400K11.11%-800K-200.00%-200K142.86%1.7M99.65%-300K-149.74%-85.3M99.77%-900K
Net income attributable to the parent company 670.48%388.5M-1.35%583.6M1.42%393.4M-61.89%1.16B-54.63%249.7M-106.00%-68.1M-44.08%591.6M27.68%387.9M95.80%3.05B49.48%550.4M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 670.48%388.5M-1.35%583.6M1.42%393.4M-61.89%1.16B-54.63%249.7M-106.00%-68.1M-44.08%591.6M27.68%387.9M95.80%3.05B49.48%550.4M
Basic earnings per share 668.09%2.67-1.96%4.010.74%2.71-61.74%8.02-54.97%1.72-105.98%-0.47-43.59%4.0930.58%2.69100.77%20.9652.19%3.82
Diluted earnings per share 665.96%2.66-1.72%41.12%2.7-61.81%7.97-54.88%1.71-105.99%-0.47-43.78%4.0729.61%2.67100.67%20.8751.60%3.79
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Cancer Research
Cancer Research
Intraday+0.04%